Nipro newsletter April 2026
tjoapck banner – feb 2026
Carterra 23/09/25
LB Bohle – 10.06.2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Merxin March 2026
Chemspec Feb 2026
the bridge – website ad 28/01/2026
Terumo 05/01
SAE Media – pre-filled syringes – East Coast 19/11/25
SAE Media – Pre-filled syringes West Coast 19/11/25
Nipro April 2026

Innovations in API Manufacturing of Small Molecule Drugs

Throughout the years, innovation has been the driving factor of many industries, allowing them to stay viable. This is also the case for the pharmaceutical industry, including API manufacturing. With the cost of new pharmaceuticals steadily rising, innovation is the only way to reduce it and ensure the future availability of new pharmaceutical treatments. Predicting which fine chemicals or APIs will be significant in the following decades is also challenging. Only through innovation is the industry capable of reacting in time to fulfil the market’s needs. This article discusses recent and future innovations in the API manufacturing industry with the potential of reducing manufacturing costs and addressing market demand accurately.

Introduction
Innovation is the practical implementation of ideas that results in introducing new goods or services or improving the offerings of existing goods or services. ISO TC 279 in the standard ISO 56000:2020 defines innovation as “a new or changed entity, realising or redistributing value”. Others have different definitions, but a common element is the focus on newness, improvement, and the spread of ideas or technologies.

The pharmaceutical industry, and therefore also the manufacturing of APIs, faces many hurdles, including the availability of a skilled workforce, supply chain disruptions, the rising cost of new therapies, and increasing environmental regulations. Innovation is the only way to decrease costs and secure the future availability of new pharmaceutical treatments. Predicting which fine chemicals or APIs will be significant in the following decades is also challenging. Only through innovation is the industry capable of reacting in time to fulfil the market’s needs.

SMI London
Biopharma group march 2026
Interpack Staubli March 2026
Silgan March 2026
Scott Pharma – 25.03.2025
Bespak – 21.05.2025
Aptar – 08/01/2026
Stoelzle – 15th May 2025
L.B. Bohle – 08.04.2025